Partnerships and co-selling ROI benchmarks and payback periods for healthcare and life sciences in the APAC region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Payback is the honest ROI question for partnerships and co-selling: how many months from first dollar spent to first dollar returned. Below are the ranges we see, split by category and starting condition.

Best-case payback for partnerships and co-selling in a category with warm demand: 60–90 days. Median: 4–6 months. Cold category with no warm inbound: 6–9 months.

The dominant driver of payback is trigger quality, not spend. One great partner is worth ten marketing hires — teams that respect this get inside the shorter range.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Sourced and influenced pipeline from partners is the leading indicator. If it moves inside the first six weeks, payback usually lands in the best case. If it stalls for a month, replan.

ROI compounds after payback. By month 12, well-run partnerships and co-selling functions typically produce 3–5x return on total cost of ownership.

Bad ROI has one signature: signing MOUs no one operationalises. Where you see broken payback, you see this pattern almost every time.

Benchmarks are useful as a sanity check, not a target. The target is the one your finance team commits to on the current-year plan; benchmarks tell you if that target is plausible.

Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.